NEI
RYTM icon

Northwest & Ethical Investments’s Rhythm Pharmaceuticals RYTM Stock Holding History

Northwest & Ethical Investments’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Sell
1,100
-1,391
-56% -$126K ﹤0.01% 462
2026
Q1 		$217K Buy
+2,491
New +$242K 0.01% 481

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Northwest & Ethical Investments's RYTM Position: Q2 2026 in Review

Northwest & Ethical Investments reduced its Rhythm Pharmaceuticals (RYTM) stake by 56% in Q2 2026, selling an estimated $126K and leaving 1,100 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #462.

Northwest & Ethical Investments first reported a position in RYTM in Q1 2026 and has held it in 2 quarters since. The position peaked at $217K in Q1 2026. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Northwest & Ethical Investments held 1,100 shares of Rhythm Pharmaceuticals worth $121K as of Q2 2026.
  • Northwest & Ethical Investments sold 1,391 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $126K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Northwest & Ethical Investments's portfolio in Q2 2026, its #462 holding.
  • Northwest & Ethical Investments first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Northwest & Ethical Investments's Rhythm Pharmaceuticals position peaked at $217K in Q1 2026.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Northwest & Ethical Investments's 13F filing for Q2 2026, filed 13 Aug 2026.